drugset
drugset / Trial / NCT01961726

Study to Evaluate the Safety and Efficacy of JVS-100 Administered to Adults With Ischemic Heart Failure

NCT01961726 ↗

Phase 1/2 Unknown 72 enrolled Juventas Therapeutics, Inc.
RandomizedParallel-groupQuadruple-blindTreatment

Summary

A phase I/II study to evaluate the safety and efficacy of JVS-100 administered by retrograde delivery to cohorts of adults with Ischemic Heart Failure.

Timeline

Start
2013-10
Primary completion
2015-08
Completion
2015-08

Drugs

EvaluationDrugModalityDoseRoute
Subject JVS-100 Other / unclassified 30 mg Other
Subject JVS-100 Other / unclassified 45 mg Other

Indications

heart failure